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On 24 November 2003, BMC Medicine published its first article. Ten years and over 900 articles later we look
back at some of the most notable milestones for the journal and discuss advances and innovations in
medicine over the last decade. Our editorial board members, Leslie Biesecker, Thomas Powles, Chris Del Mar,
Robert Snow and David Moher, also comment on the changes they expect to see in their fields over the
coming years.
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Just a few months after the Human Genome Project was
declared complete [1] BMC Medicine was launched as
an open access [2,3], open peer review journal (i.e. where
signed peer review reports are published with the article)
[4,5], with the aim of making high impact clinical
peer-reviewed research of general interest, accessible
to everyone from the basic scientist to the practicing
clinician. The journal, initially under the direction of
Pritpal Tamber and then Melissa Norton as Editor-in-
Chief, was launched amidst a raging debate about the
viability of open access publishing [6]. But open access
survived and evolved [7,8], and BMC Medicine now
ranks 8th out of 155 journals in the 2012 general and in-
ternal medical journals category of the Journal Citation
Reports [9].
While mainly focused on primary research in its early
days, the journal responded to the needs and demands
of its readers and contributors by providing, for ex-
ample, a platform for discussing controversies in med-
ical practice [10-15] and embracing social networking
technology to promote open scientific discussion and
debate [16-19]. Although proud of its Impact Factor
(IF) of 6.68, BMC Medicine recognizes that the IF is a
restrictive metric that does not fully reflect the* Correspondence: Sabina.Alam@biomedcentral.com
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2014influence of individual articles post-publication. The
journal therefore provides informative article metrics
which are immediately available on published articles -
a feature which has proven to be popular with many of
our authors [20].
Of course, innovations in publishing and technical
advances notwithstanding, BMC Medicine owes its
success to the scientific contributions made by its au-
thors, reviewers and expert editorial board members.
To celebrate its 10th anniversary, we recently reviewed
some of our most successful articles in terms of accesses
[21], citations [22] and ‘impact’ in news and social
media [23], and also summarized author and reviewer
experiences [24] and explored our author demographics
[25]. As a general medical journal with a very broad
scope, it is not possible for us to cover all the main ad-
vances in medicine featured in the journal over the last
decade, but in this editorial we present a selection of our
favorite recent content, together with predictions by our
editorial board members on possible future directions for
their respective fields of research.Translational medicine: how far have we come
with stem cells, biomarkers and ‘Omics’ research?
Stem cell research and therapy has advanced rapidly
in the last decade, and clinical trials for a wide range
of diseases are already underway [26,27]. In 2012, the
journal published an intriguing study by Zhao and
colleagues, who used Stem Cell Educator therapy toral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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stem cells from cord blood to ‘re-educate’ T cells in
patients with Type 1 diabetes, thereby restoring pan-
creatic function and reducing the need for insulin
[28]. These compelling results highlight how stem cell
therapies may become part of mainstream treatment
for many diseases.
Within the last 10 years, major advances have also
been made in biomarker research and ‘Omics’ studies
in a preclinical setting. Advances in whole genome se-
quencing have allowed the identification of genes in-
volved in a large number of diseases, and biomarkers
that indicate disease severity or susceptibility to treat-
ment are increasingly being characterized [29-32]. As
Leslie Biesecker points out (Box 1), clinical exome and
genome sequencing are already being used in the clinic
for diagnostic and prognostic purposes. However, Biesecker
also indicates that these new technologies are not with-
out problems and alludes to the role the journal plays
in ensuring the latest research is appropriately validated
and disseminated.Box 1
Leslie G. Biesecker
National Human Genome Research Institute, USA
Genomics has provided new modes of discovery in the basic
sciences and is now doing the same for clinical research. It has
already started to change medical practice with clinical exome
and genome sequencing. These two assays are now being
used in thousands of patients, for example, to provide a
genome-wide diagnostic assay for uncharacterized disorders of
birth defects or neurologic disorders and in tumor sequencing
to identify targets for cancer therapeutics. BMC Medicine has a
critical role to fulfil in this process by providing a forum for
critical evaluation of these new technologies. The objective
could not be more important - to preserve what works well in
medicine and remake what does not. It is hard to imagine a
more exciting time for our field.
The field of medical oncology is moving at a breathtaking
speed. A plethora of new agents are now available based on
the molecular biology of specific tumors. The next step is to
identify subsets of patients who benefit from therapy and
move away from ‘one size fits all’ strategies. Therefore,
biomarkers predicting response to these therapies are
required. The application of whole genome sequencing, novel
tracers within the context of functional imaging and
circulating biomarkers, such as free circulating tumor DNA will
be important pieces in this complex puzzle. There is also a
need to develop therapies which focus on inducing longer
remission rather than temporary disease controls.
A collaborative international approach is required to achieve
these goals.Despite the discovery of many biomarkers for cancer
in particular, so far very few have been used within the
clinical setting [33], which is partly due to a lack of
consistency and clarity in the reporting of prognostic
tumor markers. This prompted the development of
the Reporting Recommendations for Tumor Marker
Prognostic Studies (REMARK) checklist [34], whichwas updated in 2012 by Altman and colleagues [35] and
more recently, the development of criteria to address
the lack of scientific rigor when evaluating preclinical
evidence to support translation of omics-based predictors
to clinical trials [36,37].
The continued identification of new genes and bio-
markers specific to disease subtypes and individual pa-
tients is essential for translation into personalized
medicine, in terms of estimating both disease risk and
response to therapy. As highlighted above, the field
which has seen the most progress in this area is clinical
oncology, and Thomas Powles explains what further
changes are required to achieve effective personalized
cancer therapies (Box 2).Evidence-based medicine: education,
communication and collaboration
There has been increasing international focus on pub-
lic health initiatives, development of healthcare pol-
icies and evidence-based guidelines to improve medical
practice [38,39]. This is embedded in effective education
strategies, which is evident from a continuing medical
education intervention aimed at strengthening links
between evidence-based and values-based medicine in
healthcare personnel [40]. Researchers found this inter-
vention led to improved values, such as openness to
change, which are essential for improving medical care.
Box 4
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a more collaborative approach to decision-making be-
tween clinicians, patients and policy makers needs to
be developed, and highlights the importance of trans-
parency and communication.Box 3
Chris Del Mar
Bond University Gold Coast, Australia
Medicine will enter a new phase of concern about decreasing gains
for increasing harms - including not just cost but also over-diagnosis
and over-treatment. The medical profession has not been able
hitherto to demonstrate an ability to make such cost-benefit
decisions sensibly alone, and therefore there will be increasing input
from society; increased demand for shared decision-making with
the patient; and more directives from government. One important
element of quality will soon be considered to be the extent to
which the clinician has explicitly, clearly and carefully com-
municated the evidence in such a way that every patient is
in a position to express a preference for the range of man-
agement options available. Evidence-based medicine will no
longer be some hidden activity that clinicians may (or may
not) engage in: it will become the currency expected for
patient-clinician communication.
Since I started work in Africa 30 years ago the landscape of
science and research capacity has changed enormously. It is no
longer legitimate to make excuses that model-based computing,
laboratory science or gene sequencing can only be done in the
north. The infrastructure and human capacity now exists in
Africa to provide the best possible science for public health
problems that face the continent. A fundamental requirement
for any form of development is that countries have to take
ownership of their problems. The next decade requires an active
promotion by governments in Africa, and international partners
that support regional development, of the expanding cohorts of
African scientists who champion the very highest standards of
medical and public health science within the region. Generating
new research from within Africa holds untold promise. Unlike
external research agendas and funding 30 years ago, this new
research will have a much greater and much faster impact on
the health of communities in Africa over the next decade.There is also increasing focus on involving researchers
based in low-to-middle income countries as principal
investigators in local research projects. This is especially
important as local knowledge helps to ask the ‘right’
questions in health research, ensures the best available
evidence is accumulated and that all ethical aspects have
been considered [41-43]. This is vital to guide health-
care policies and identify new tools and strategies; the
consequences of not doing so is evident from a recent
bibliometric analysis of childhood immunization research
output from Africa. Since the onset of the Expanded
Program on Immunization in 1974, vaccine research
productivity in Africa has skewed toward those funded
privately, with minimal research input from African
authors, suggesting a need for better communication
among all stakeholders [44]. Robert Snow points out
(Box 4), conditions for research are now improving in
Africa, and it is important that local researchers and
governments work closely to drive the research output
from these regions forward.Enhancing research with reporting guidelines
Without clear guidelines for conducting and analyzing
medical research, there is a limit to how far medicine
can progress, and the last few years have seen many im-
portant improvements in reporting standards. In 2010,
BMC Medicine co-published the updated CONSORT
(CONsolidated Standards of Reporting Trials) statement
by Schulz and colleagues [45]. This statement guides
authors on the reporting of two-parallel design ran-
domized controlled trials by using a checklist and flow
diagram based on the latest methodological evidence.
More recently, in response to the particular challenges in
reporting economic evaluations of health interventions,
the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) was published [46]. This statement
consolidates existing guidelines with the aim of providing
more ‘user-friendly’ guidance for researchers and editors.
As research methods become more sophisticated, so
too do the methods via which literature analysis can be
conducted. The ‘RAMESES’ (Realist and Meta-review
Evidence Synthesis: Evolving Standards) statement [47,48]
was published to provide researchers, institutes and jour-
nals with guidance on how to conduct these new forms of
literature analysis, and adherence to the guidelines will lead
to quality assurance and uniform reporting of studies.
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Moher explains (Box 5) that journals and editors play a
key role in providing peer reviewers and authors with
the tools and guidance to ensure that medical research
is appropriately reported.Box 5
David Moher
Ottawa Hospital Research Institute, Canada
To reduce the considerable waste of inadequately published
research, medical journals will need to develop long-term innovative
strategies, such as developing core competencies for editors and
peer reviewers, as well as accreditation programs for journals. More
immediately, they can help foster greater implementation of
reporting guidelines by facilitating the development of applications
that can take manuscript content and automatically populate
reporting guideline checklists. Such information can provide
immediate feedback about the completeness of reporting of
manuscripts to authors, editors and peer reviewers.We hope you have enjoyed our selection of just some of
the most exciting content from BMC Medicine, and hope
this has prompted you to seek out favorites of your own.
As an open access general medical journal, we aim to
promote better informed clinical decisions and improved
therapies. We will continue to publish content that has
the potential to improve clinical practice, research and
reporting. We especially encourage debate on health related
issues not just within the clinical community, but also for
the general public who should be, after all, the primary
beneficiaries of the research.
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